An ultralow dose of the NADPH oxidase inhibitor diphenyleneiodonium (DPI) is an economical and effective therapeutic agent for the treatment of colitis-associated colorectal cancer
"The present study revealed that an ultralow dose of DPI, with no significant systemic toxicity involved, may be an effective way to prevent the occurrence and development of CAC"
Thank you Johan! Very helpful one!
And nice to see your real picture in your profile 🙂 https://www.cancertreatmentsresearch.com/community/profile/johan/